» Articles » PMID: 15268757

Genome-scale Expression Profiling of Hutchinson-Gilford Progeria Syndrome Reveals Widespread Transcriptional Misregulation Leading to Mesodermal/mesenchymal Defects and Accelerated Atherosclerosis

Overview
Journal Aging Cell
Specialties Cell Biology
Geriatrics
Date 2004 Jul 23
PMID 15268757
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disease with widespread phenotypic features resembling premature aging. HGPS was recently shown to be caused by dominant mutations in the LMNA gene, resulting in the in-frame deletion of 50 amino acids near the carboxyl terminus of the encoded lamin A protein. Children with this disease typically succumb to myocardial infarction or stroke caused by severe atherosclerosis at an average age of 13 years. To elucidate further the molecular pathogenesis of this disease, we compared the gene expression patterns of three HGPS fibroblast cell strains heterozygous for the LMNA mutation with three normal, age-matched cell strains. We defined a set of 361 genes (1.1% of the approximately 33,000 genes analysed) that showed at least a 2-fold, statistically significant change. The most prominent categories encode transcription factors and extracellular matrix proteins, many of which are known to function in the tissues severely affected in HGPS. The most affected gene, MEOX2/GAX, is a homeobox transcription factor implicated as a negative regulator of mesodermal tissue proliferation. Thus, at the gene expression level, HGPS shows the hallmarks of a developmental disorder affecting mesodermal and mesenchymal cell lineages. The identification of a large number of genes implicated in atherosclerosis is especially valuable, because it provides clues to pathological processes that can now be investigated in HGPS patients or animal models.

Citing Articles

Painful diabetic neuropathy is associated with accelerated epigenetic aging.

Kwiatkowska K, Garagnani P, Bonafe M, Bacalini M, Calzari L, Gentilini D Geroscience. 2025; .

PMID: 39847262 DOI: 10.1007/s11357-025-01516-w.


Angiopoietin-2 reverses endothelial cell dysfunction in progeria vasculature.

Vakili S, Izydore E, Losert L, Cabral W, Tavarez U, Shores K Aging Cell. 2024; 24(2):e14375.

PMID: 39422121 PMC: 11822663. DOI: 10.1111/acel.14375.


Cellular Senescence as a Targetable Risk Factor for Cardiovascular Diseases: Therapeutic Implications: Family Series.

Kumar M, Yan P, Kuchel G, Xu M JACC Basic Transl Sci. 2024; 9(4):522-534.

PMID: 38680957 PMC: 11055207. DOI: 10.1016/j.jacbts.2023.12.003.


The secretome atlas of two mouse models of progeria.

Quintana-Torres D, Valle-Cao A, Bousquets-Munoz P, Freitas-Rodriguez S, Rodriguez F, Lucia A Aging Cell. 2023; 22(10):e13952.

PMID: 37565451 PMC: 10577534. DOI: 10.1111/acel.13952.


The Molecular and Cellular Basis of Hutchinson-Gilford Progeria Syndrome and Potential Treatments.

Batista N, Desai S, Perez A, Finkelstein A, Radigan R, Singh M Genes (Basel). 2023; 14(3).

PMID: 36980874 PMC: 10048386. DOI: 10.3390/genes14030602.